<DOC>
	<DOCNO>NCT00272740</DOCNO>
	<brief_summary>The primary objective study ass activity fulvestrant postmenopausal woman advance breast cancer fail treatment non-steroidal steroidal aromatase inhibitor estimate Clinical Benefit Rate</brief_summary>
	<brief_title>SAKK - Trial Evaluate Antitumor Efficacy FaslodexÂ® After Aromatase Inhibitor Failure Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Histological/cytological confirmation breast cancer progression treatment aromatase inhibitor At least one measurable nonmeasurable lesion Prior treatment breast cancer 2 different hormonal agent More 1 chemotherapy advance disease Presence lifethreatening metastatic visceral disease</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>fulvestrant</keyword>
	<keyword>Faslodex</keyword>
	<keyword>hormonotherapy</keyword>
	<keyword>aromatase inhibitor failure</keyword>
	<keyword>Advanced breast cancer</keyword>
</DOC>